

Market Announcement

7 July 2025

Island Pharmaceuticals Limited (ASX: ILA) – Trading Halt

Trading in the securities of Island Pharmaceuticals Limited ('ILA') will be halted at the request of ILA, pending the release of an announcement by ILA.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 9 July 2025; or
- the release of the announcement to the market.

ILA's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

7 July 2025

Ms Melissa Kostopoulos
Adviser, Listings Compliance
ASX Compliance Pty Limited
Level 4, North Tower, Rialto
525 Collins Street
MELBOURNE VIC 3000

By email: Melissa.Kostopoulos@asx.com.au

Dear Ms Kostopoulos

Island Pharmaceuticals Ltd (ASX:ILA) (Island Pharmaceuticals/Company) – Request for Trading Halt

In accordance with listing rule 17.1, Island Pharmaceuticals requests a halt to the trading in its ordinary shares quoted on the Australian Securities Exchange (ASX) with effect from prior to commencement of trading today, 7 July 2025.

In accordance with ASX Listing Rule 17.1, Island Pharmaceuticals provides the following information in relation to the request:

- (a) The trading halt is requested pending an announcement by Island Pharmaceuticals regarding the execution of Asset Purchase Agreement with BioCryst Pharmaceuticals, Inc in relation to the Galidesivir program;
- (b) Island Pharmaceuticals requests that the trading halt remain in place until the earlier of open trade on 9 July 2025 or the release of an announcement by the Company; and
- (c) Island Pharmaceuticals is seeking the trading halt to assist in managing its disclosure obligations and to maintain an orderly market in the trading of the Company's shares.

Island Pharmaceuticals confirms that it is not aware of any reason why the trading halt should not be granted and is not aware of any other information necessary to inform the market about the trading halt.

Yours sincerely



Cameron Jones
CFO and Company Secretary

Approved by the board of Island Pharmaceuticals